Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors
Open Access
- 13 October 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (20) , 4958-4967
Abstract
Purpose: Myxoid liposarcoma is a common subtype of liposarcoma. It is associated in more than 90% of cases with the chromosomal translocation t(12;16)(q13;p11) leading to the fusion FUS-CHOP gene that is responsible for the oncogenic transformation of preadipocytes. Recently the marine natural product trabectedin has shown highly selective activity for myxoid liposarcoma, even in the most aggressive round-cell subtype. Experimental Design: Fragments of 17 sarcomas were transplanted s.c. in female athymic NCr-nu/nu mice. Xenografts were established and characterized by morphology, fluorescence in situ hybridization analysis for the translocation and reverse transcriptase-PCR analysis for fusion transcripts. Trabectedin was injected i.v. Results: Seven of 17 tumors grew as continuous xenografts, five of them being myxoid liposarcoma of the round-cell subtype. The chromosomal rearrangement and fusion transcripts in different passages were the same as in the human tumors from which they were derived. The responsiveness to trabectedin in type II myxoid liposarcoma xenografts was as high as in patients. The pathologic response was associated with the presence of the FUS-CHOP fusion gene, indicating that the drug does not totally eradicate the disease. Type III myxoid liposarcoma xenografts seemed much less sensitive to trabectedin, confirming previous clinical observations. Conclusions: This study reports for the first time the characterization of human myxoid liposarcoma xenografts that adequately mimic the biological and pharmacologic features of the human tumor. These models offer a useful tool for investigating the mechanism of selectivity of trabectedin, testing new combinations with this drug and evaluating novel therapies for myxoid liposarcoma. Clin Cancer Res; 16(20); 4958–67. ©2010 AACR.Keywords
This publication has 17 references indexed in Scilit:
- A Review of Trabectedin (ET-743): A Unique Mechanism of ActionMolecular Cancer Therapeutics, 2010
- Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma CellsCancer Research, 2010
- Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution seriesAnnals of Oncology, 2009
- Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumorsMolecular Cancer Therapeutics, 2009
- FUS-DDIT3 Prevents the Development of Adipocytic Precursors in Liposarcoma by Repressing PPARγ and C/EBPα and Activating eIF4EPLOS ONE, 2008
- Role of homologous recombination in trabectedin-induced DNA damageEuropean Journal of Cancer, 2008
- Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743Proceedings of the National Academy of Sciences, 2007
- Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1‐DDIT3 fusionGenes, Chromosomes and Cancer, 2007
- Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine ProductionCancer Research, 2005
- Silencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancerGenes, Chromosomes and Cancer, 2002